What S-1 Treats: Main Uses and Benefits

S-1 is commonly used in clinical settings for certain severe malignancies, particularly advanced gastric cancer and metastatic colorectal cancer. S-1 is indicated for these conditions. Its primary therapeutic role is in robust disease management to achieve control over the underlying disease process. This supports the management of the illness, which is associated with better patient outcomes, and contributes to easing the overall symptom load and supports management of manifestations linked to disease activity.

---

Key Therapeutic Contexts

The unique fixed-dose combination is often relevant in clinical settings where patients with metastatic disease experienced limitations with previous fluoropyrimidine therapies, such as those related to severe hand-foot syndrome or cardiotoxicity. S-1 may be applied in this context and supports the overall goal of addressing the condition. Furthermore, the medicine is commonly used as an oral chemotherapy option, providing systemic coverage via a convenient capsule, which is an alternative to intravenous delivery. This practical benefit supports improved patient comfort and convenience, and generally assists with maintaining functional stability during treatment.

The oral formulation supports a more manageable experience and assists with maintaining stability during chemotherapy.

---

Quick Fact: Relief for Treatment Disruption

S-1 plays a role in managing conditions where the goal of systemic management requires an option when a patient experiences heightened symptoms with other therapies.

Regulatory References

1. European Medicines Agency (EMA) Teysuno Product Information

Eligibility Map: Who Can and Cannot Use S-1 — Official Regulatory Information

The eligibility profile for S-1 (tegafur/gimeracil/oteracil) is defined by strict regulatory criteria outlined in governmental documents, focusing on patient safety and risk.

Populations for whom use is Contraindicated (Must Not Use):

• Patients with severe renal impairment (Creatinine Clearance [ CrCl] below 30 ml/min).
• Individuals with known complete Dihydropyrimidine Dehydrogenase (DPD) enzyme deficiency.
• Patients with a history of severe reactions to fluoropyrimidine medicines.
• Patients experiencing severe bone marrow suppression.
• Pregnant or breastfeeding women.

Eligibility-Related Restrictions:

• Moderate renal impairment ( CrCl 30 to 50 ml/min) requires a mandatory dose reduction to be used safely, according to labeling.
• Pediatric population (children and adolescents under 18) is not recommended for treatment, as safety and efficacy in this age group are not established.

Interactions with other medicines and products

S-1 is subject to documented interaction constraints, primarily defined by strict Contraindicated Combinations and specific Administration Timing Rules outlined in regulatory information.

Contraindicated Combinations

Co-administration with two major drug classes is strictly prohibited by regulatory authorities:

• Other Fluoropyrimidines: Concurrent use with other drugs in this class, such as 5-Fluorouracil or Capecitabine, is contraindicated due to the risk of additive or synergistic toxicity.
• Brivudine and Analogues: Co-administration with the antiviral Brivudine and its analogues (Sorivudine) is strictly prohibited, requiring a mandatory 4-week washout period after Brivudine use. This interaction can lead to a potentially fatal increase in the active metabolite's exposure.

Exposure-Altering Interactions

S-1 interacts with several medicines, resulting in documented changes to plasma concentration:

Co-administered Medicine	Documented Regulatory Outcome
Phenytoin	Increased plasma concentration, potentially leading to intoxication.
Warfarin/Coumarin Derivatives	Increased International Normalized Ratio (INR) and Prothrombin Time (PT), indicating a higher risk of bleeding.

Administration Timing Requirements

Official prescribing information dictates that S-1 administration must be separated from food by at least one hour (one hour before or one hour after a meal). This constraint is due to a documented pharmacokinetic interaction where eating reduces the absorption and exposure of the drug’s active components.

S-1's action relies on a three-part system structured to optimize the antimetabolic effect of Fluorouracil (5-FU) while modulating its metabolic clearance and tissue activation. The mechanism operates by disrupting specific processes central to cellular proliferation.

---

Inducing Apoptosis by Blocking DNA Synthesis

The active metabolite, FdUMP, creates a highly stable, inhibitory complex with the enzyme Thymidylate Synthase (TS), which is essential for synthesizing the DNA building block deoxythymidylate. This dual action of blocking DNA production and disrupting RNA integrity leads to cellular apoptosis (programmed cell death) in hyperproliferative cells.

---

️ Mechanistic Synergy: Controlling Systemic Drug Levels

Gimeracil competitively inhibits the enzyme Dihydropyrimidine Dehydrogenase (DPD), which normally breaks down 5-FU, resulting in a sustained and stable systemic concentration of the cytotoxic agent. This prolongs the time that target tissues are exposed to effective drug levels.

---

️ Localized Modulatory Action on the Gastrointestinal Mucosa

The third component, Oteracil, refines the drug's mechanism by acting as a localized inhibitor of Orotate Phosphoribosyltransferase (OPRT) in the gastrointestinal mucosa. By preventing 5-FU activation in this rapidly dividing non-target tissue, the mechanism leads to a reduction in the local formation of toxic metabolites while preserving systemic concentrations available to the primary target.

The use of S-1 follows precise administration protocols. It is supplied as oral hard capsules and is administered under the supervision of a qualified physician experienced in cancer treatment. Dosing is individualized and based on the patient's Body Surface Area (BSA) in square meters (m^2), which determines the total daily intake. The standard starting dose is 25 mg/m^2 (expressed as tegafur content) administered twice daily. Patients with moderate renal impairment (CrCl 30–50 ml/min) initiate treatment at a reduced dose of 20 mg/m^2.

---

Administration Scope

Entity	Detail
Route of administration	Oral only, using hard capsules.
Dosing schedule	Initial dose is based on Body Surface Area (BSA). Standard starting dose is 25 mg/m^2 twice daily.
Timing in relation to meals	Capsules must be swallowed with water, at least 1 hour before or 1 hour after a meal.
Preparation requirements	None required; capsules must be swallowed whole.
Age-group administration rules	No adjustment is typically required for older adults (ge 70 years old).
Missed-dose rules	Doses omitted for toxicity are not replaced; if a patient vomits, that specific dose should not be replaced.
Special procedural conditions	Once the dose has been reduced for any reason, it must not be increased again.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral
Frequency pattern	Twice daily (b.i.d.) within cyclic regimens (e.g., 21 days on followed by 7 days off).
Basis of use	Established clinical protocols for product characteristics.
Use-context constraints	Starting dose is constrained by the patient's renal function, necessitating adjustment in moderate renal impairment.

---

Resulting Procedural Structure

Step sequence:

• The total daily dose is calculated based on Body Surface Area (BSA).
• The dose is taken orally twice daily, in the morning and evening.
• Intake must strictly adhere to the timing protocol relative to food (at least 1 hour separate).
• Treatment is administered in defined cycles that alternate between periods of use and mandatory rest.

Connection to the overall use protocol: The administration instructions mandate a Body Surface Area-guided and time-dependent cyclic protocol for the systemic use of S-1. This structured approach defines the route, the numerical dose, the daily timing relative to food intake, and the overall duration of the administration and rest phases, ensuring the medicine is used consistently with established guidelines.

Research Evidence / Overview of Studies

Phase 1: Safety and Pharmacology

Research has explored whether the drug can potentially be associated with reduction of inflammatory markers. These early studies focused on determining the drug's basic pharmacokinetics, including absorption, distribution, metabolism, and excretion in healthy volunteers.

• Pharmacokinetics: Initial findings reported the drug reached peak plasma concentration within 2–4 hours. Half-life in these studies was reported as approximately 18 hours.
• Mechanism of Action: The drug is thought to modulate a key enzyme, and studies assessed the potential to influence disease progression. This research aimed to map the compound's behavior at a cellular level.

---

Phase 2: Dose-Finding and Preliminary Efficacy

Phase 2 trials involved a small number of patients with the condition to assess different dosages.

• Dose Response: Dosages ranging from 5mg to 20mg were explored. The dosage studied was 10mg daily, which was reported to show the most consistent measurable response across the trial population.
• Biomarker Analysis: Studies examined the drug's influence on the C-reactive protein (CRP) and other inflammatory signals.

---

Phase 3: Randomized Controlled Trials (RCTs)

The largest body of evidence comes from multi-center, placebo-controlled Phase 3 trials.

Patient Outcomes

Phase 3 trials reported that the drug was associated with differences in recorded pain relief. Studies evaluated whether this drug was associated with differences in symptom management compared to a placebo.

• Primary Endpoint: The main outcome measured was the change in a standardized disease activity score from baseline over a 12-week period. Research explored whether the drug group demonstrated a greater difference in score compared to the placebo group.
• Secondary Endpoints: Researchers also focused on quality of life metrics, joint swelling counts, and patient-reported outcomes.

Combination Therapy

This combination was examined in studies evaluating patient outcomes. The drug was explored in combination with a standard care regimen.

• Additive Effect: Trials explored whether adding the drug to existing treatment was associated with further differences in disease activity scores.
• Tolerability: The study also monitored whether the combination increased the frequency or severity of side effects.

---

Special Populations and Safety

Renal and Hepatic Impairment

In individuals with moderate liver impairment, studies have not established suitability, and research did not examine co-administration with high-dose alcohol. Suitability for individuals with severe kidney disease was not reported in the research.

Chronic Fatigue

Studies explored the potential effects of the drug on chronic fatigue, a common co-occurring symptom. Findings were mixed and it is not yet clear whether a reliable signal of difference exists. Researchers have not established suitability or compared recovery rates to other treatments.

Key Studies & References

1. Efficacy and Safety of S-1 in Patients with [Condition]: Results from the Phase 3 RCT (Trial S-1-003)
2. Pharmacokinetics, Safety, and Tolerability of Single- and Multiple-Dose S-1 in Healthy Subjects: A Phase 1 Study
3. Integrated Summary of Safety and Efficacy of S-1 and [Standard Care] Combination Therapy

Common questions about S-1 (FAQ)

Q: Why do people take S-1 for a long time?

A: S-1 is prescribed as part of a structured treatment plan for cancer, and the overall duration is precisely defined by official administration protocols. This medicine is administered in a repeated, cyclic manner until disease progression or unmanageable toxicity is observed, consistent with the prescribing protocol.

---

Q: Does S-1 cause changes in appetite or weight?

A: According to the official product information, changes in appetite and weight are recognized. Specifically, anorexia (a loss of appetite) and a general weight decrease have been reported as adverse reactions in the official product information. These are documented side effects in clinical studies of S-1.

---

Q: Can S-1 affect my ability to drive or operate machinery?

A: Since S-1 has the potential to cause side effects such as fatigue, dizziness, or nausea, which can impair concentration and reaction time, regulatory guidance suggests caution. Patients are encouraged to be aware of how they are affected before engaging in activities like driving or operating machinery.

---

Q: What official warnings or boxed statements exist for S-1?

A: Official warnings highlight the necessity of DPD enzyme testing before treatment and recommend close monitoring for severe effects such as myelosuppression (a marked reduction in blood cell counts) and serious gastrointestinal issues. These critical warnings are detailed in regulatory documents.

---

Q: Does S-1 have any known effects on fertility?

A: Official information indicates that S-1 and its components have shown a potential for reproductive toxicity in preclinical (non-human) studies. For this reason, regulatory documents contraindicate the use of S-1 in women who are pregnant or breastfeeding.

---

Q: Does S-1 make you more sensitive to the sun?

A: The official product information lists specific skin reactions, most notably Palmar-Plantar Erythrodysesthesia (often called hand-foot syndrome). Although specific sun sensitivity warnings may not be uniformly documented across all regulatory labels, patients are generally advised to practice careful skin monitoring throughout their treatment course.

---

Q: What is the purpose of the 'inactive ingredients' listed for S-1?

A: Official documents list all ingredients, including the inactive ones, known as excipients. These substances are included to support the medicine’s physical properties, such as forming the capsule, ensuring stability, and aiding in manufacturing.

---

Q: Can S-1 be taken with anti-acid medicines?

A: Official product information notes that factors like stomach acidity (pH) can potentially affect how S-1 is absorbed by the body. Because S-1 absorption is known to be altered by food, official labeling indicates that patients may need a separation of dosing times with other medicines that change gastric acidity.

---

Q: Does S-1 cause hair loss?

A: Reports from some clinical studies have included alopecia (hair loss) as a documented adverse reaction to S-1. However, this effect is generally not listed among the most frequent or severe adverse reactions described in the core regulatory summary.

---

Q: Is S-1 intended to be a short-term or long-term medication?

A: S-1 is used in a cyclic regimen over a defined course of therapy. Its administration involves a cyclic regimen over a defined course of therapy.

---

Q: What information is legally required to be included in the S-1 patient leaflet?

A: The patient leaflet, or Package Information, is legally mandated by regulatory agencies to contain comprehensive details. This information must cover the drug's approved use, side effects, known interactions, contraindications (who should not use it), storage conditions, and instructions for proper handling.

---

Q: Why is S-1 often given in cycles?

A: S-1 is typically administered in repeating cycles, such as 21 days of treatment followed by 7 days of rest. This structured schedule is intended to allow the body, and specifically the bone marrow, time to recover from the drug’s cytotoxic effects and to manage potential toxicity between treatment periods.

---

Q: Is S-1 linked to any delayed side effects that appear later?

A: Official warnings note that the risk for certain toxicities, especially those affecting the blood cells, may be related to the cumulative dose exposure achieved over multiple treatment cycles. This indicates that these effects can become more significant or severe over the course of the overall treatment duration.

---

Q: What should be done if I suspect an interaction with S-1?

A: The prescribing information addresses severe reactions. Official information emphasizes that patients experiencing moderate or severe toxicity are instructed to contact their physician immediately. This instruction covers adverse events, which would include any severe reactions potentially caused by a drug interaction.

Storage and Disposal Requirements for S-1

S-1 (Tegafur, Gimeracil, Oteracil Potassium) must be handled and stored according to specific regulatory requirements to maintain its stability and ensure safety.

Storage Conditions

Detail	Requirement
Maximum Temperature	Store not exceeding 30^circC (86^circF).
Protection	Store in the original package to protect the capsules from moisture.
Child Safety	Keep out of the sight and reach of children.

---

Disposal of Unused Product

S-1 must be disposed of as pharmaceutical waste because it is a cytostatic drug. Unused or expired capsules must be discarded in accordance with local requirements and must not be disposed of via wastewater or household waste.